PolyTherics appoints Dr John Burt chief business officer

pharmafile | November 16, 2010 | Appointment | Manufacturing and Production, Research and Development |  Dr John Burt, PolyTherics, appointment, manufacturing and production, protein engineering, research and development 

UK protein engineering company PolyTherics has appointed Dr John Burt as chief business officer.

He was previously chief executive of Thiakis, which he co-founded with Professor Steve Bloom of Imperial College in 2004 and subsequently sold to Wyeth in 2008.

John’s prior roles have included positions with Imperial Innovations, GSK and Vernalis and he has been active in advising early-stage biotech companies on strategy, finance and business development issues.

PolyTherics’ chief executive Keith Powell said: “We are delighted that John has joined us and are sure that his experience, notably with Thiakis and GSK, will be invaluable.

“We now have a management team which, together with our chairman, Ken Cunningham, has the breadth of experience with both biotech and large pharma companies to take PolyTherics to the next stage in its evolution.”

Biopharmaceutical company PolyTherics has substantial expertise in the targeted modification of proteins and proteins with therapeutic potential, and its most advanced programme is an interferon alpha PEGylated that has just entered development.